Page last updated: 2024-08-16

vorinostat and belinostat

vorinostat has been researched along with belinostat in 51 studies

Research

Studies (51)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	5 (9.80)	29.6817
2010's	39 (76.47)	24.3611
2020's	7 (13.73)	2.80

Authors

Authors	Studies
Binaschi, M; Fattori, D; Paris, M; Porcelloni, M	1
Altamura, S; De Francesco, R; Gallinari, P; Jones, P; Lahm, A; Neddermann, P; Rowley, M; Serafini, S; Steinkühler, C	1
Amici, R; Bigogno, C; Boggio, R; Cappa, A; Carrara, S; Cataudella, T; Colombo, A; di Ventimiglia, SJ; Dondio, G; Fusar, F; Gagliardi, S; Gianti, E; Mai, A; Mercurio, C; Minucci, S; Moroni, M; Munari, D; Pain, G; Regalia, N; Sartori, L; Thaler, F; Varasi, M; Vultaggio, S	1
Bradner, JE; Grachan, ML; Greenberg, EF; Haggarty, SJ; Mazitschek, R; Warnow, T; West, N	1
Abate, A; Bigogno, C; Boggio, R; Carenzi, G; Cataudella, T; Dal Zuffo, R; Dondio, G; Fulco, MC; Mai, A; Mercurio, C; Minucci, S; Rozio, MG; Thaler, F; Varasi, M	1
Bonday, Z; Chang, JW; Chen, D; Deng, W; Dymock, BW; Fang, L; Goh, KC; Goh, KL; Goh, SK; Hu, C; Kantharaj, E; Khng, HH; Khoo, ML; Lee, KC; Liu, X; Lu, T; Lye, PL; Ng, MC; Poulsen, A; Sangthongpitag, K; Sun, ET; Wang, H; Wang, X; Wood, JM; Wu, X; Yeo, P; Yu, N	1
Atadja, P; Cao, X; Chen, CH; Cho, YS; Davis, NR; Eckman, J; Fan, J; Fekete, A; Firestone, B; Flynn, J; Green, J; Growney, JD; Holmqvist, M; Hsu, M; Jansson, D; Jiang, L; Kwon, P; Liu, G; Lombardo, F; Lu, Q; Majumdar, D; Meta, C; Perez, L; Pu, M; Ramsey, T; Remiszewski, S; Shultz, MD; Skolnik, S; Traebert, M; Urban, L; Uttamsingh, V; Wang, P; Whitebread, S; Whitehead, L; Yan-Neale, Y; Yao, YM; Zhou, L	1
Atadja, P; Bickford, S; Buteau, K; Cao, X; Chen, C; Cho, YS; Davis, N; Fan, J; Holmqvist, M; Hsu, M; Jiang, L; Liu, G; Lu, Q; Patel, C; Selvaraj, M; Shultz, M; Suresh, JR; Urban, L; Wang, P; Whitehead, L; Yan-Neale, Y; Zhang, H; Zhou, L	1
He, Y; Liu, R; Ning, C; Yu, N; Zhou, M	1
Ai, T; Chen, L; Geraghty, RJ; Qiu, L; Xu, Y	1
Chang, CY; Chao, YH; Hsu, CM; Huang, HL; Huang, YZ; Kumar, S; Lee, HY; Li, YH; Liou, JP; Mehndiratta, S; Su, CJ; Sung, TY; Yang, CR	1
He, F; Hou, J; Li, J; Li, X; Qu, Y; Wang, X; Wu, J; Xu, W; Yu, C	1
Christianson, DW; Hai, Y	1
Cheng, F; Dong, N; Huang, J; Jiang, X; Li, J; Lin, P; Liu, M; Lu, W; Ouyang, P; Tang, Y; Wu, D; Wu, Z; Xu, Z; Yao, X; Zeng, M; Zhang, C; Zou, S	1
Forgione, M; Hailu, GS; Mai, A; Robaa, D; Rotili, D; Sippl, W	1
Hsu, CM; Huang, HL; Liou, JP; Mehndiratta, S; Pan, SL; Su, CJ; Wang, RS; Wu, YW	1
Chen, L; Chen, Y; He, L; Huang, L; Shao, M; Shen, M; Wang, F; Wang, T; Yang, Z; Zheng, L; Zhou, Y	1
Chen, D; Goh, WH; Soh, CK; Wang, H	1
Guo, S; Liu, J; Wang, G; Yang, L; Zhang, C; Zhang, Q; Zheng, S; Zhong, Q	1
Chou, CJ; Ding, Q; Inks, ES; Xu, W; Zang, J; Zhang, Y; Zhao, C	1
Andrews, KT; Antonova-Koch, Y; Avery, VM; Diedrich, D; Duffy, S; Fisher, G; Gebru, T; Hansen, FK; Held, J; Hesping, E; Kurz, T; Meister, S; Schöler, A; Stenzel, K; Winzeler, EA	1
Adhikari, N; Amin, SA; Banerjee, S; Jha, T	1
He, F; Lv, J; Qu, Y; Wu, J; Xu, A; Yu, C; Zhang, Q; Zhang, X	1
Kochetkov, SN; Konduktorov, KA; Kozlov, MV; Shcherbakova, AS	1
Brindisi, M; Brogi, S; Butini, S; Campiani, G; Gemma, S; Saraswati, AP	1
Li, Y; Tang, Z; Wan, Y; Yan, C; Yan, M	1
Codd, R; Gotsbacher, MP; Roth, L	1
Chiba, DE; Dos Santos, JL; Lopes, JR	1
Adam, GC; Barnard, RJO; Beshore, DC; Burlein, C; Coleman, PJ; Cox, CD; Gallicchio, SN; Holloway, MK; Klein, DJ; Krosky, D; Lemaire, W; Myers, RW; Patel, S; Plotkin, MA; Powell, DA; Rada, V; Wolkenberg, SE	1
Abdeldayem, A; Adile, AA; Bukhari, S; Cabral, AD; de Araujo, ED; Garcha, HK; Gawel, JM; Geletu, M; Gunning, PT; Gwynne, W; Hassan, MM; Israelian, J; Manaswiyoungkul, P; Nawar, N; Olaoye, OO; Radu, TB; Raouf, YS; Sedighi, A; Singh, SK; Suk, Y; Toutah, K; Venugopal, C	1
Emanuele, S; Lauricella, M; Tesoriere, G	1
Bishton, MJ; Harrison, SJ; Prince, HM	1
Choi, J; Hwang, JJ; Hyun, YL; Jang, S; Kim, CS; Kim, MJ; Kim, YS; Lee, JH; Lee, JS; Ro, S	1
Choi, J; Hwang, JJ; Jang, S; Jeong, IG; Kim, CS; Kim, DE; Kim, MJ; Lee, JH; Ro, S	1
Chen, SS; Dong, M; Feng, FY; Hu, XS; Shi, YK; Xing, PY	1
Biersack, B; Di Fazio, P; Lingelbach, S; Schobert, R	1
Behera, J; Jayaprakash, V; Sinha, BN	1
Bok, I; Copland, JA; Marlow, LA; Smallridge, RC	1
Dekker, FJ; Feringa, BL; Ourailidou, ME; Szymanski, W; Velema, WA	1
Duvic, M	1
Devaraj, VC; Mullangi, R; Srinivas, NR; Suresh, PS	1
Andersson, BS; Brammer, JE; Champlin, RE; Hosing, C; Li, Y; Liu, Y; Murray, D; Nieto, Y; Valdez, BC	1
Figg, WD; Goey, AK; Peer, CJ; Sissung, TM	1
Andrews, KT; Arnold, MS; Chua, MJ; Fairlie, DP; Lamotte, S; Lancelot, J; Pierce, RJ; Prina, E; Skinner-Adams, TS; Späth, GF; Xu, W	1
De Bosscher, K; De Cauwer, L; Dendoncker, K; Libert, C; Timmermans, S; Van Looveren, K	1
Cao, F; Dekker, FJ; Zwinderman, MRH	1
Banerjee, NS; Broker, TR; Chow, LT; Moore, DW	1
Chen, J; Wang, S; Yu, Z; Zhang, Q	1
Docherty, JR; Kenny, RG; Marmion, CJ; Ude, Z	1
Fujii, K; Jimura, N; Kanekura, T; Kondo, T; Qiao, Z; Tsuchiya, R; Yoshimatsu, Y	1
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ	1

Reviews

14 review(s) available for vorinostat and belinostat

Article	Year
Histone deacetylase inhibitors: from bench to clinic. Journal of medicinal chemistry, 2008, Mar-27, Volume: 51, Issue:6 Topics: Animals; Antineoplastic Agents; Cell Proliferation; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Humans; Molecular Structure; Neoplasms	2008
Lysine Deacetylase Inhibitors in Parasites: Past, Present, and Future Perspectives. Journal of medicinal chemistry, 2017, 06-22, Volume: 60, Issue:12 Topics: Animals; Antiparasitic Agents; Drug Repositioning; Helminth Proteins; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Leishmania; Plasmodium; Protozoan Proteins; Schistosoma; Toxoplasma; Trypanosoma	2017
Histone deacetylase 8 (HDAC8) and its inhibitors with selectivity to other isoforms: An overview. European journal of medicinal chemistry, 2019, Feb-15, Volume: 164 Topics: Drug Design; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Protein Isoforms; Repressor Proteins; Structure-Activity Relationship	2019
Indole: A privileged scaffold for the design of anti-cancer agents. European journal of medicinal chemistry, 2019, Dec-01, Volume: 183 Topics: Antineoplastic Agents; Drug Design; Drug Screening Assays, Antitumor; Humans; Indoles; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasms; Proto-Oncogene Proteins c-pim-1; Tubulin	2019
HIV latency reversal agents: A potential path for functional cure? European journal of medicinal chemistry, 2021, Mar-05, Volume: 213 Topics: Anti-HIV Agents; CD4-Positive T-Lymphocytes; Histone Deacetylase Inhibitors; HIV Infections; HIV-1; Humans; Molecular Structure; Virus Latency	2021
Histone deacetylase inhibitors: apoptotic effects and clinical implications (Review). International journal of oncology, 2008, Volume: 33, Issue:4 Topics: Antineoplastic Agents; Apoptosis; Chromatin; Depsipeptides; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Models, Biological; Models, Chemical; Neoplasms; Protein Structure, Tertiary; Sulfonamides; Vorinostat	2008
Clinical studies of histone deacetylase inhibitors. Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Jun-15, Volume: 15, Issue:12 Topics: Antibiotics, Antineoplastic; Benzamides; Clinical Trials as Topic; Depsipeptides; Drug Therapy, Combination; Enzyme Inhibitors; Hematologic Neoplasms; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Panobinostat; Pyridines; Pyrimidines; Sulfonamides; Vorinostat	2009
[Progress in cancer treatment with histone deacetylase inhibitor]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2013, Volume: 35, Issue:7 Topics: Aminopyridines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials as Topic; Depsipeptides; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Indoles; Neoplasms; Panobinostat; Sulfonamides; Vorinostat	2013
Histone deacetylase inhibitors: a review on class-I specific inhibition. Mini reviews in medicinal chemistry, 2015, Volume: 15, Issue:9 Topics: Depsipeptides; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Neoplasms; Patents as Topic; Protein Binding; Sulfonamides; Vorinostat	2015
Histone Deacetylase Inhibitors for Cutaneous T-Cell Lymphoma. Dermatologic clinics, 2015, Volume: 33, Issue:4 Topics: Depsipeptides; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Lymphoma, T-Cell, Cutaneous; Panobinostat; Skin Neoplasms; Sulfonamides; Vorinostat	2015
Review of bioanalytical assays for the quantitation of various HDAC inhibitors such as vorinostat, belinostat, panobinostat, romidepsin and chidamine. Biomedical chromatography : BMC, 2017, Volume: 31, Issue:1 Topics: Aminopyridines; Animals; Benzamides; Chromatography, High Pressure Liquid; Depsipeptides; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Neoplasms; Panobinostat; Sulfonamides; Tandem Mass Spectrometry; Vorinostat	2017
Pharmacogenomics and histone deacetylase inhibitors. Pharmacogenomics, 2016, Volume: 17, Issue:16 Topics: Depsipeptides; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Panobinostat; Pharmacogenetics; Sulfonamides; Valproic Acid; Vorinostat	2016
The Process and Strategy for Developing Selective Histone Deacetylase 3 Inhibitors. Molecules (Basel, Switzerland), 2018, Mar-02, Volume: 23, Issue:3 Topics: Antineoplastic Agents; Chemistry Techniques, Synthetic; Depsipeptides; Drug Design; Epigenesis, Genetic; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Indoles; Inflammation; Isoenzymes; Neoplasm Proteins; Neoplasms; Neurodegenerative Diseases; Panobinostat; Structure-Activity Relationship; Sulfonamides; Vorinostat	2018
Histone Deacetylases (HDACs) Guided Novel Therapies for T-cell lymphomas. International journal of medical sciences, 2019, Volume: 16, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Autophagy; Cytokines; Depsipeptides; Epigenesis, Genetic; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Lymphoma, T-Cell; Molecular Targeted Therapy; Sulfonamides; Vorinostat	2019

Other Studies

37 other study(ies) available for vorinostat and belinostat

Article	Year
Probing the elusive catalytic activity of vertebrate class IIa histone deacetylases. Bioorganic & medicinal chemistry letters, 2008, Mar-15, Volume: 18, Issue:6 Topics: Acetylation; Benzamides; Catalysis; Cells, Cultured; Escherichia coli; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Kidney; Molecular Structure; Mutation; Peptides, Cyclic; Pyridines; Pyrimidines; Sulfonamides	2008
Synthesis and biological evaluation of N-hydroxyphenylacrylamides and N-hydroxypyridin-2-ylacrylamides as novel histone deacetylase inhibitors. Journal of medicinal chemistry, 2010, Jan-28, Volume: 53, Issue:2 Topics: Acrylamides; Antineoplastic Agents; Benzene Derivatives; Cell Proliferation; Colonic Neoplasms; Drug Stability; Enzyme Inhibitors; HeLa Cells; Histone Deacetylase Inhibitors; Humans; Pyridines; Structure-Activity Relationship; Xenograft Model Antitumor Assays	2010
Chemical phylogenetics of histone deacetylases. Nature chemical biology, 2010, Volume: 6, Issue:3 Topics:	2010
Discovery, synthesis, and pharmacological evaluation of spiropiperidine hydroxamic acid based derivatives as structurally novel histone deacetylase (HDAC) inhibitors. Journal of medicinal chemistry, 2011, Apr-28, Volume: 54, Issue:8 Topics: Administration, Oral; Animals; Biological Availability; Cell Line, Tumor; Drug Evaluation, Preclinical; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Magnetic Resonance Spectroscopy; Mice; Molecular Structure; Spectrometry, Mass, Electrospray Ionization	2011
Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile. Journal of medicinal chemistry, 2011, Jul-14, Volume: 54, Issue:13 Topics: Administration, Oral; Animals; Antineoplastic Agents; Benzimidazoles; Biological Availability; Cell Line, Tumor; Dogs; Drug Screening Assays, Antitumor; Female; Histone Deacetylase 1; Histone Deacetylase Inhibitors; Humans; Isoenzymes; Mice; Mice, Inbred BALB C; Mice, Nude; Microsomes, Liver; Neoplasm Transplantation; Quantitative Structure-Activity Relationship; Rats; Rats, Wistar; Stereoisomerism	2011
Optimization of the in vitro cardiac safety of hydroxamate-based histone deacetylase inhibitors. Journal of medicinal chemistry, 2011, Jul-14, Volume: 54, Issue:13 Topics: Acrylamides; Animals; Antineoplastic Agents; Drug Screening Assays, Antitumor; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Half-Life; HCT116 Cells; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; In Vitro Techniques; Mice; Mice, Nude; Microsomes, Liver; Models, Molecular; Neoplasm Transplantation; Patch-Clamp Techniques; Radioligand Assay; Rats; Rats, Sprague-Dawley; Stereoisomerism; Structure-Activity Relationship; Tissue Distribution; Transplantation, Heterologous	2011
The design, synthesis and structure-activity relationships of novel isoindoline-based histone deacetylase inhibitors. Bioorganic & medicinal chemistry letters, 2011, Aug-15, Volume: 21, Issue:16 Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Histone Deacetylase 1; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Isoindoles; Molecular Structure; Stereoisomerism; Structure-Activity Relationship	2011
Design, synthesis and biological evaluation of indeno[1,2-d]thiazole derivatives as potent histone deacetylase inhibitors. Bioorganic & medicinal chemistry letters, 2013, Jun-01, Volume: 23, Issue:11 Topics: Binding Sites; Cell Proliferation; Drug Design; Drug Screening Assays, Antitumor; HCT116 Cells; Heterocyclic Compounds, 3-Ring; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; MCF-7 Cells; Molecular Docking Simulation; Protein Structure, Tertiary; Structure-Activity Relationship; Thiazoles	2013
Hydroxamic acids block replication of hepatitis C virus. Journal of medicinal chemistry, 2015, Jan-22, Volume: 58, Issue:2 Topics: Antiviral Agents; Hepacivirus; Histone Deacetylase Inhibitors; Hydroxamic Acids; Structure-Activity Relationship; Virus Replication	2015
2-(Phenylsulfonyl)quinoline N-hydroxyacrylamides as potent anticancer agents inhibiting histone deacetylase. European journal of medicinal chemistry, 2016, Oct-21, Volume: 122 Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Histone Deacetylase Inhibitors; Histone Deacetylases; Histones; Humans; Male; Mice; Quinolines; Structure-Activity Relationship; Tubulin; Xenograft Model Antitumor Assays	2016
Design, synthesis, and preliminary bioactivity evaluation of N Chemical biology & drug design, 2017, Volume: 89, Issue:1 Topics: Cell Proliferation; Drug Design; HeLa Cells; Histone Deacetylase Inhibitors; Humans; Indoles; Molecular Docking Simulation; Phthalic Acids	2017
Histone deacetylase 6 structure and molecular basis of catalysis and inhibition. Nature chemical biology, 2016, Volume: 12, Issue:9 Topics: Animals; Biocatalysis; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Models, Molecular; Molecular Structure; Structure-Activity Relationship; Substrate Specificity; Zebrafish	2016
Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis. Journal of medicinal chemistry, 2017, 03-09, Volume: 60, Issue:5 Topics: Acute Lung Injury; Animals; Epoxide Hydrolases; Female; Histone Deacetylase Inhibitors; Idiopathic Pulmonary Fibrosis; Leukotriene B4; Mice; Mice, Inbred C57BL; Neutrophils	2017
4-Indolyl-N-hydroxyphenylacrylamides as potent HDAC class I and IIB inhibitors in vitro and in vivo. European journal of medicinal chemistry, 2017, Jul-07, Volume: 134 Topics: Acrylamides; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Histone Deacetylase 1; Histone Deacetylase 2; Histone Deacetylase Inhibitors; Humans; Indoles; Male; Mice; Mice, Nude; Neoplasms; Prostate; Prostatic Neoplasms; Xenograft Model Antitumor Assays	2017
Structure-based design, synthesis and in vitro antiproliferative effects studies of novel dual BRD4/HDAC inhibitors. Bioorganic & medicinal chemistry letters, 2017, 09-01, Volume: 27, Issue:17 Topics: Antineoplastic Agents; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Histone Deacetylase 1; Histone Deacetylase Inhibitors; Humans; Models, Molecular; Molecular Structure; Nuclear Proteins; Structure-Activity Relationship; Transcription Factors	2017
Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma. Journal of medicinal chemistry, 2018, 02-22, Volume: 61, Issue:4 Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Screening Assays, Antitumor; Heterografts; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Liver Neoplasms; Liver Neoplasms, Experimental; Mice; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Pyrimidines; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays	2018
Biocompatible Boron-Containing Prodrugs of Belinostat for the Potential Treatment of Solid Tumors. ACS medicinal chemistry letters, 2018, Feb-08, Volume: 9, Issue:2 Topics:	2018
Discovery of meta-sulfamoyl N-hydroxybenzamides as HDAC8 selective inhibitors. European journal of medicinal chemistry, 2018, Apr-25, Volume: 150 Topics: Antineoplastic Agents; Benzamides; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Molecular Docking Simulation; Molecular Structure; Repressor Proteins; Structure-Activity Relationship	2018
One-pot, multi-component synthesis and structure-activity relationships of peptoid-based histone deacetylase (HDAC) inhibitors targeting malaria parasites. European journal of medicinal chemistry, 2018, Oct-05, Volume: 158 Topics: Acetylation; Antimalarials; Hep G2 Cells; Histone Deacetylase Inhibitors; Histones; Humans; Malaria, Falciparum; Peptoids; Plasmodium falciparum; Protozoan Proteins	2018
Design, synthesis and activity evaluation of indole-based double - Branched HDAC1 inhibitors. Bioorganic & medicinal chemistry, 2019, 04-15, Volume: 27, Issue:8 Topics: Binding Sites; Cell Line, Tumor; Cell Proliferation; Drug Design; Histone Deacetylase 1; Histone Deacetylase Inhibitors; Humans; Indoles; Molecular Docking Simulation; Protein Isoforms; Protein Structure, Tertiary; Structure-Activity Relationship	2019
Synthesis of N'-propylhydrazide analogs of hydroxamic inhibitors of histone deacetylases (HDACs) and evaluation of their impact on activities of HDACs and replication of hepatitis C virus (HCV). Bioorganic & medicinal chemistry letters, 2019, 08-15, Volume: 29, Issue:16 Topics: Antiviral Agents; Dose-Response Relationship, Drug; Hepacivirus; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydrazines; Microbial Sensitivity Tests; Molecular Structure; Repressor Proteins; Structure-Activity Relationship; Virus Replication	2019
Old but Gold: Tracking the New Guise of Histone Deacetylase 6 (HDAC6) Enzyme as a Biomarker and Therapeutic Target in Rare Diseases. Journal of medicinal chemistry, 2020, 01-09, Volume: 63, Issue:1 Topics: Animals; Biomarkers; Cell Line; Epigenesis, Genetic; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Humans; Mice; Protein Processing, Post-Translational; Rare Diseases	2020
Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors. Journal of medicinal chemistry, 2020, 10-22, Volume: 63, Issue:20 Topics: Chromatography, Affinity; Coordination Complexes; Crystallography, X-Ray; Dose-Response Relationship, Drug; Drug Discovery; Humans; Imino Acids; Metalloproteins; Metals, Heavy; Models, Molecular; Molecular Structure; Structure-Activity Relationship	2020
Redefining the Histone Deacetylase Inhibitor Pharmacophore: High Potency with No Zinc Cofactor Interaction. ACS medicinal chemistry letters, 2021, Apr-08, Volume: 12, Issue:4 Topics:	2021
Discovery of HDAC6-Selective Inhibitor NN-390 with Journal of medicinal chemistry, 2022, 02-24, Volume: 65, Issue:4 Topics: Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Computer Simulation; Drug Discovery; Drug Screening Assays, Antitumor; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Humans; Medulloblastoma; Models, Molecular; Molecular Docking Simulation; Neoplastic Stem Cells; Structure-Activity Relationship	2022
A novel histone deacetylase inhibitor, CG0006, induces cell death through both extrinsic and intrinsic apoptotic pathways. Anti-cancer drugs, 2009, Volume: 20, Issue:9 Topics: Acetylation; bcl-X Protein; Caspases; Cell Cycle; Cell Death; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Enzyme Inhibitors; Gene Expression; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Piperidines; Sulfonamides; Tubulin; Vorinostat	2009
HDAC inhibitors synergize antiproliferative effect of sorafenib in renal cell carcinoma cells. Anticancer research, 2012, Volume: 32, Issue:8 Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Sulfonamides; Von Hippel-Lindau Tumor Suppressor Protein; Vorinostat	2012
4,5-Diaryl imidazoles with hydroxamic acid appendages as anti-hepatoma agents. Investigational new drugs, 2015, Volume: 33, Issue:1 Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Indoles; Liver Neoplasms; Panobinostat; Sulfonamides; Vorinostat	2015
RhoB upregulation leads to either apoptosis or cytostasis through differential target selection. Endocrine-related cancer, 2015, Volume: 22, Issue:5 Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Blotting, Western; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Drug Synergism; Flow Cytometry; Histone Deacetylase 1; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Immunoenzyme Techniques; Membrane Proteins; Paclitaxel; Proto-Oncogene Proteins; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; rhoB GTP-Binding Protein; RNA, Messenger; Sulfonamides; Thyroid Carcinoma, Anaplastic; Transcriptional Activation; Tumor Cells, Cultured; Up-Regulation; Vorinostat	2015
Light-Controlled Histone Deacetylase (HDAC) Inhibitors: Towards Photopharmacological Chemotherapy. Chemistry (Weinheim an der Bergstrasse, Germany), 2015, Nov-09, Volume: 21, Issue:46 Topics: Antineoplastic Agents; Apoptosis; Cell Proliferation; HeLa Cells; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Light; Panobinostat; Sulfonamides; Vorinostat	2015
Differential effects of histone deacetylase inhibitors on cellular drug transporters and their implications for using epigenetic modifiers in combination chemotherapy. Oncotarget, 2016, Sep-27, Volume: 7, Issue:39 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; Cell Death; Cell Line, Tumor; Cell Proliferation; Depsipeptides; DNA Methylation; Drug Synergism; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Lymphoma; Multidrug Resistance-Associated Proteins; Panobinostat; RNA, Messenger; Sulfonamides; Up-Regulation; Vorinostat	2016
Effect of clinically approved HDAC inhibitors on Plasmodium, Leishmania and Schistosoma parasite growth. International journal for parasitology. Drugs and drug resistance, 2017, Volume: 7, Issue:1 Topics: Acetylation; Administration, Oral; Animals; Depsipeptides; HEK293 Cells; Histone Deacetylase Inhibitors; Histone Deacetylases; Histones; Humans; Hydroxamic Acids; Indoles; Inhibitory Concentration 50; Leishmania; Life Cycle Stages; Malaria; Mice; Panobinostat; Parasitemia; Plasmodium berghei; Plasmodium knowlesi; Schistosoma mansoni; Sulfonamides; Vorinostat	2017
The nature of the GRE influences the screening for GR-activity enhancing modulators. PloS one, 2017, Volume: 12, Issue:7 Topics: A549 Cells; Dexamethasone; Drug Resistance; Gene Expression Profiling; Gene Expression Regulation; Genes, Reporter; Glucocorticoids; High-Throughput Screening Assays; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Luciferases; Receptors, Glucocorticoid; Response Elements; Signal Transduction; Sulfonamides; Transcriptome; Vorinostat	2017
Vorinostat, a pan-HDAC inhibitor, abrogates productive HPV-18 DNA amplification. Proceedings of the National Academy of Sciences of the United States of America, 2018, 11-20, Volume: 115, Issue:47 Topics: Apoptosis; Bcl-2-Like Protein 11; Cells, Cultured; DNA Repair; DNA Replication; DNA-Binding Proteins; DNA, Viral; Histone Deacetylase Inhibitors; Histones; Human papillomavirus 18; Humans; Hydroxamic Acids; Keratinocytes; Mucous Membrane; Oncogene Proteins, Viral; Panobinostat; Papillomavirus Infections; Sulfonamides; Tumor Suppressor Protein p53; Vorinostat	2018
Vorinostat and Belinostat, hydroxamate-based anti-cancer agents, are nitric oxide donors. Journal of inorganic biochemistry, 2020, Volume: 206 Topics: Animals; Antineoplastic Agents; Aorta; Guanylate Cyclase; Hydroxamic Acids; Nitric Oxide Donors; Rats; Ruthenium; Sulfonamides; Vasodilation; Vasodilator Agents; Vorinostat	2020
Kinome profiling analysis identified Src pathway as a novel therapeutic target in combination with histone deacetylase inhibitors for cutaneous T-cell lymphoma. Journal of dermatological science, 2021, Volume: 101, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Depsipeptides; Drug Screening Assays, Antitumor; Drug Synergism; Gene Expression Profiling; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Imidazoles; Lymphoma, T-Cell, Cutaneous; Oligonucleotide Array Sequence Analysis; Protein Kinase Inhibitors; Pyridazines; Skin Neoplasms; src-Family Kinases; Sulfonamides; Vorinostat	2021
Identification of potent Yes1 kinase inhibitors using a library screening approach. Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15 Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship	2013